Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Onglyza® (saxagliptin tablets) and Kombiglyze® XR (saxagliptin/metformin extended-release tablets) have been permanently discontinued, according to manufacturer AstraZeneca.
A recent posting on the Food and Drug Administration’s (FDA) Drug Shortages tracker indicates that both products were discontinued because of a business decision and not due to safety or efficacy-related concerns.
Onglyza contains saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Kombiglyze XR is a combination of saxagliptin and metformin, a biguanide. Both treatments are indicated for use an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes.
A list of alternative treatment options is available here. Therapies that fall into the same pharmacological class and are indicated for diabetes treatment include Januvia (sitagliptin), Nesina (alogliptin), Tradjenta (linagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin), Jentadueto XR (linagliptin/metformin), and Kazano (alogliptin/metformin).
References:
- US Food and Drug Administration. Saxagliptin Tablets. FDA Drug Shortages. Accessed March 22, 2023. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Saxagliptin+Tablets&st=d&tab=tabs-4&panels=0.
- Saxagliptin and Metformin Hydrochloride XR Tablets. FDA Drug Shortages. Accessed March 22, 2023. https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Saxagliptin+and+Metformin+Hydrochloride+XR+Tablets&st=d&tab=tabs-4&panels=0.
